Xcout IntelAlto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Subscribe to see Alto Neuroscience, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Alto Neuroscience, Inc. at a glance
Alto Neuroscience, Inc. is a biotech company headquartered in Mountain View, United States, founded in 2019. It is publicly listed (ANRO) with a market capitalisation of $1.1B. Xcout tracks 27 named people at Alto Neuroscience, Inc., including Nicholas C. Smith (CFO & President).
Alto Neuroscience, Inc. leadership
- Nicholas C. SmithCFO & President
- Michael C. HanleyChief Operating Officer
- Michael HanleyChief Operating Officer
- Nick SmithChief Financial Officer and Chief Business Officer
- Adam SavitzChief Medical Officer
- Erin R. McQuadeGeneral Counsel, Chief Administrative Officer & Corporate Secretary
21 more named people on record for Alto Neuroscience, Inc., with roles, board committees and tenure — see the full roster →
Alto Neuroscience, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Debt | $45M | 8 named | |
| — | $35M | 10 named |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Get Alto Neuroscience, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Alto Neuroscience, Inc. in Xcout Intel
- 27 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access